Abbott Vascular
Drug Eluting Stent Program

Krishna Sudhir, MD, PhD, FACC

Medical Director, Global Clinical Science

Abbott Vascular – Cardiac Therapies

December 8, 2006

Abbott
A Promise for Life

XIENCE™ V Everolimus Eluting CSS Components

MULTI-LINK VISION®
Stent

MULTI-LINK VISION®
Stent Delivery System



Everolimus



Fluoropolymer



CAUTION: XIENCE™ V is an investigational device. Limited by Federal (U.S.) law to investigational use only.

Abbott Vascular

Drug Eluting Stents

- The benefits of DES outweigh potential risks
- All DES are not the same
  - There are differences in platforms, polymers, drugs and elution rates
- New therapies are best understood and advanced through robust pre-clinical, pre-market and post-market clinical research
- As new technologies evolve, efficacy and safety profiles improve over time

Drug Eluting Stents

- Cardiovascular Research Foundation (CRF) analysis of 9 clinical databases (Stone, Leon, Mehran, Kirtane, Pocock, Fahy): Data presented at TCT, October 2006
- Pre-specified analysis of safety and efficacy variables
- No differences were observed in death and MI out to 4 years for Cypher and Taxus, compared to BMS

Drug Eluting Stents

Pre-clinical assessment of DES:

- Acute safety is achieved via
  - Minimal vessel injury
  - Complete stent apposition
  - Thromboresistant materials
- Long term safety requires
  - Rapid re-endothelialization
  - A functional endothelial layer
  - Minimal chronic inflammation
  - No persistent fibrin

Drug Eluting Stents

Differences in platforms, polymers, drugs and elution rates

CYPHER®	TAXUS®	ENDEAVOR™	XIENCE™ V
			
Strut Thickness:	Strut Thickness:	Strut Thickness:	Strut Thickness:
140 um	**132 um**	**91 um**	**81 um**
Polymer Thickness:	Polymer Thickness:	Polymer Thickness:	Polymer Thickness:
12.6 um	**16 um**	**5.3 um**	**7.6 um**
Total:	**Total:**	**Total:**	**Total:**
152.6 um	**148 um**	**96.3 um**	**88.6 um**

3.0 mm diameter stents, 500x magnification

Data on file at Abbott Vascular

CAUTION: Endeavor and XIENCE™ V are investigational devices. Limited by Federal (U.S.) law to investigational use only.

Abbott Vascular

14-Day Rabbit Iliac Re-endothelialization Study:
Representative Photomicrographs of Competitive Stents



Photos on file at Abbott Vascular, Shown with permission from Dr. Renu Virmani

CAUTION: Endeavor and XIENCE™ V are investigational devices. Limited by Federal (U.S.) law to investigational use only.

Abbott Vascular

14-Day Rabbit Iliac Re-endothelialization Study:
Endothelialization of Competitive Stents



Data on File at Abbott Vascular

CAUTION: Endeavor and XIENCE™ V are investigational devices. Limited by Federal (U.S.) law to investigational use only.

Abbott Vascular

Drug Eluting Stents:
From Pre-clinical Data to Clinical Results

- Differences in design yield different pre-clinical data and potentially different clinical results

SPIRIT Family of Trials evaluating XIENCE™ V



CAUTION: XIENCE™ V is an investigational device. Limited by Federal (U.S.) law to investigational use only.

Abbott Vascular

SPIRIT FIRST

In-stent Late Loss at 6 Months

SPIRIT II



CAUTION: XIENCE™ V is an investigational device. Limited by Federal (U.S.) law to investigational use only.

Abbott Vascular

SPIRIT FIRST & SPIRIT II: Stent Thrombosis

- Spirit First (2 yr F/U):
  - No Thrombosis in either XIENCE™ V or VISION Control through two years
- SPIRIT II (9 month F/U) : 1 thrombotic event in each group (XIENCE™ V 0.5% vs Taxus Express 1.3%) within 60 days
- Re-adjudication of Spirit First and Spirit II stent thrombosis data using Dublin/ARC definitions ongoing

Abbott Vascular XIENCE™ V DES

In conclusion,

- Platform (ML Vision®): Market leading bare metal stent
- Pre-clinical data for XIENCE™ V demonstrated excellent endothelialization and limited chronic inflammation
- SPIRIT First and SPIRIT II have shown superior efficacy and encouraging safety data
- The SPIRIT family of clinical trials will evaluate >10,000 patients with long term (up to 5 year) follow-up


Abbott
A Promise for Life